Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Comment by dakyon Jan 14, 2011 1:05am
302 Views
Post# 17970583

RE: RE: Waiting on results...

RE: RE: Waiting on results...

I am quoting .......   "

 

  "  ............   A Phase I clinical study for NRM8499 was initiated by BELLUS Health during the first quarter of 2010. The randomized, double-blind, placebo-controlled study will investigate the safety, tolerability and pharmacokinetic profile of NRM8499 in a group of up to 84 young and elderly healthy subjects. The Phase I clinical study is expected to conclude in the second half of 2010. .............  "

  


  "........After over 15 years of significant scientific research, including clinical testing with over 2,000 individuals in 50 U.S. and 17 Canadian medical centres, and hundreds of millions of dollars invested, VIVIMIND™ has been scientifically proven to protect memory function, based on the naturally occurring ingredient, homotaurine. VIVIMIND™ is now available for consumers.

VIVIMIND™ is a patented product based on the ingredient homotaurine, a naturally occurring amino acid with unique properties found in certain seaweed. VIVIMIND™ (homotaurine) is proven to have beneficial effects on brain structure, as well as memory ...  "

Bullboard Posts